KAUST's Computational Bioscience Research Center (CBRC) and King Abdulaziz City for Science and Technology (KACST) have collaborated on research into methicillin-resistant Staphylococcus aureus (MRSA) within Saudi Arabia, starting in July 2018. The two-year project aims to understand MRSA drug resistance mechanisms specific to the Kingdom and its regions, with the goal of developing public health strategies. The project involves sequencing samples and performing bioinformatics analysis to support a network of researchers in the country. Why it matters: This initiative enhances Saudi Arabia's capacity to predict, prevent, and control infectious diseases, aligning with national health objectives and building local expertise in computational bioscience.
KAUST researchers in collaboration with NASA discovered 26 new bacterial species thriving in NASA cleanrooms. These species possess genetic traits that suggest they can survive the harsh conditions of space travel. The study analyzed the genetic traits of extremophiles to understand the risk of their transfer in space missions. Why it matters: This research supports Saudi Arabia's space vision and KAUST's role in microbial and space biology, aiding NASA in anticipating microorganisms encountered in space missions.
The KAUST Pathogen Genomics Laboratory (PGL), led by Professor Arnab Pain, is using DNA and RNA sequencing to study the SARS-CoV-2 virus. The lab is part of KAUST's Rapid Research Response Team (R3T), supporting Saudi healthcare stakeholders in combating COVID-19. Pain and his Ph.D. student Sharif Hala are partnering with the Saudi-CDC and Ministry of Health hospitals to sequence Saudi SARS-CoV-2 samples. Why it matters: This effort provides crucial data for understanding and monitoring the virus's spread and evolution within the Kingdom, informing public health strategies.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
MBZUAI researchers developed a machine-learning method to predict antimicrobial resistance (AMR) by analyzing electronic health records. The system predicts if a patient will experience AMR when prescribed an antibiotic or if infected with a bacterium. Published in Scientific Reports, the innovation helps physicians identify patients at risk for AMR by using patient demographics, lab results, and physician notes. Why it matters: This approach can help combat the rise of drug-resistant bacteria by providing timely predictions and supporting more informed prescription decisions.
KAUST and the SFDA co-hosted the "Trends in Microbiome and Digital One Health" conference from October 30 to November 1, 2023, featuring 35 speakers from five continents. Discussions centered on microbiome science, digital tools for tracking microbial epidemiology, and their roles in the One Health concept. The conference facilitated the formation of a consortium for microbiome and Digital One Health research. Why it matters: This event highlights Saudi Arabia's growing focus on leveraging microbiome research and digital technologies to address public health challenges and promote international collaboration in the field.
A KAUST-led team developed NIRVANA, a portable, briefcase-sized device for rapid detection and sequencing of SARS-CoV-2, influenza, and other viruses. The test utilizes isothermal recombinase amplification (RPA) and was validated on clinical samples and wastewater. NIRVANA can differentiate SARS-CoV-2 strains and doesn't require expensive infrastructure. Why it matters: This innovation enables rapid, decentralized virus detection and surveillance, crucial for pandemic response and monitoring new variants across the region.